Ipsen pulls cancer drug Tazverik from market over safety risks
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
AI Summary: Ipsen has removed its EZH2 inhibitor Tazverik (tazemetostat) from the U.S. market after safety issues flagged by an independent monitoring review. The withdrawal forces clinicians to pivot to alternative therapies and triggers regulatory and clinical re‑examination of the drug’s benefit‑risk profile for patients previously depending on it.
FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products
Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…
AI Summary: The FDA is consolidating multiple safety reporting systems into a single public Adverse Event Monitoring System to centralize reports for drugs, biologics, vaccines, cosmetics and animal products. The move aims to improve transparency, reduce fragmented reporting, and streamline monitoring — a tidy solution if it works as promised.
New FDA bonus pilot to address 'workforce challenges'
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
AI Summary: The FDA has introduced a pilot program offering performance bonuses to expedite regulatory reviews, aiming to tackle reviewer workload and improve timeliness. Funded partly by industry user fees, the initiative seeks to reward faster, high‑quality reviews while balancing independence and efficiency—proof that carrots sometimes replace the endless stick of overtime.
FDA lifts hold on Intellia trial
Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…
AI Summary: The FDA has lifted clinical holds on Intellia Therapeutics’ Phase 3 gene‑editing trials, allowing the company to resume patient enrollment and advance its nexiguran (nex‑z) development program. Regulators appear satisfied with submitted safety updates, clearing a major regulatory hurdle and moving the gene-editing program back toward its clinical milestones.
FDA vaccine chief to step down in April
Ella Jeffries / beckershospitalreview - Vinay Prasad, MD, the FDA’s top regulator of vaccines and cell and gene therapies, will step down at the end of April, an agency spokesperson confirmed to Becker’s. Dr. Prasad joined the agency in 2025 on a one-year sabbatical from the University of Calif…
AI Summary: Vinay Prasad, the FDA’s top regulator for vaccines and cell and gene therapies, will step down at the end of April amid mounting criticism over controversial decisions that reportedly overrode agency scientists and spooked stakeholders. His exit follows prolonged internal and external disputes about regulatory judgment and leadership style.
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy
livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
AI Summary: An experimental treatment markedly cut seizures and eased symptoms in children with Dravet syndrome, offering families dramatic improvements where few options existed. Early clinical data show promising safety and efficacy signals, but researchers caution larger, longer trials and regulatory review are needed before this becomes a routine option.
Boehringer wins accelerated approval for first-line use of lung cancer drug
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.
Patient dies in MacroGenics' cancer study, FDA puts trial on hold
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
AI Summary: Regulators have imposed a partial hold on a Phase 2 gynecologic cancer trial after multiple serious adverse events, including one patient death and additional safety incidents. The pause mandates review of trial protocols and safety monitoring before enrollment can resume, highlighting the inherent risks when experimental therapies meet human biology.
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
AI Summary: The FDA released draft guidance creating a regulatory pathway to speed individualized and N-of-1 cell and gene therapies for ultra‑rare diseases. The framework clarifies evidence expectations, manufacturing and safety-monitoring options, and trial design flexibility to help get bespoke treatments from bench to bedside faster — no miracles promised, just fewer bureaucratic speed bumps.
ChatGPT Health performance in a structured test of triage recommendations
Ashwin Ramaswamy / nature - Nature Medicine, Published online: 23 February 2026; doi:10.1038/s41591-026-04297-7A stress test of ChatGPT Health triage revealed missed high-risk emergencies and inconsistent activation of suicide-crisis safeguards, raising safety concerns for consumer-…
AI Summary: A structured, independent evaluation found that ChatGPT Health—an AI tool offering consumer triage and health guidance—missed or misclassified high-risk cases and gave inconsistent advice. Researchers and clinicians raised safety concerns about relying on the system for urgent medical decision-making, calling for tighter oversight and validation before broad public deployment.
Gilead to acquire cell therapy manufacturer for $7.8B
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.
‘You’re not the Lone Ranger’ anymore: Medical education evolves for team-based care
Paige Twenter / beckershospitalreview - As U.S. healthcare increasingly adopts team-based care, medical schools are working to prepare students for future care delivery models, according to a Feb. 18 article from the Association of American Medical Colleges. Team-based care, or a coordinated ba…
AI Summary: A multi‑agent AI system called DeepRare has proven it can outpace physicians in head‑to‑head rare‑disease diagnosis tests, promising to shorten the notorious “diagnostic odyssey.” Industry leaders tout this as a practical diagnostic aid, while experts caution about validation, integration into clinical workflows and equity in access before it replaces any human judgment.
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
AI Summary: The FDA has rejected Disc Medicine’s application for its rare-disease candidate even after granting an accelerated review pathway, concluding the submitted evidence did not demonstrate sufficient benefit. The setback stalls a high-profile regulatory push and requires the company to collect more robust clinical data before re‑seeking approval.
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
AI Summary: A Nature Medicine study presents plasma p‑tau217 “clocks” that estimate when symptomatic Alzheimer’s disease is likely to begin, offering a blood-based forecast years before cognitive decline appears. The test could reshape trial enrollment, early intervention timing and patient counseling—validation and access hurdles remain, but at least worried boomers get a calendar to dread.
FDA formalizes one pivotal trial policy via NEJM perspective
Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...
AI Summary: The FDA has moved to make a single pivotal trial the new default for drug approvals, abandoning the long-standing two-study standard to speed access and ease OTC transitions. The policy, outlined by agency leaders and discussed in a NEJM perspective, raises questions about evidence thresholds and downstream safety monitoring. Welcome to faster approvals — now let's hope that lone study behaves.
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
AI Summary: After renewed discussions with the company, the FDA reversed its earlier stance and agreed to accept Moderna’s amended application for an mRNA seasonal influenza vaccine. Regulators will now evaluate the submitted safety and efficacy data to determine whether the shot meets approval standards — a regulatory about-face that will keep flu-watchers and investors awake.
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test
Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…
AI Summary: Ocular Therapeutix’s investigational drug Axpaxli met its primary endpoint in a pivotal Phase 3 trial, showing superiority to Regeneron’s Eylea for wet age‑related macular degeneration. The company plans an FDA submission, positioning Axpaxli as a potential new first‑line therapy if regulators agree — a welcome development for patients tired of frequent injections.
Can medical AI lie? Large study maps how LLMs handle health misinformation
medicalxpress - Medical artificial intelligence (AI) is often described as a way to make patient care safer by helping clinicians manage information. A new study by the Icahn School of Medicine at Mount Sinai and collaborators confronts a critical vulnerability: when a m…
AI Summary: A broad analysis — including Mount Sinai research — shows large language models and medical AI systems can propagate false or misleading health claims when presented in realistic clinical language. Findings expose safety gaps, underline risks of unchecked deployment, and call for tighter guardrails, validation and clinician oversight before clinical use.
Lilly appeals retatrutide classification ruling in case that could impact compounders
Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...
AI Summary: Eli Lilly is contesting a regulatory classification decision for its next‑generation obesity shot while simultaneously stockpiling doses ahead of potential U.S. approval. The dispute has broader implications for compounding pharmacies and has coincided with lawsuits accusing telehealth vendors and compounders of selling unapproved oral GLP‑1 alternatives — a messy intersection of commerce, regulation and patient safety.
Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents
Abraham Shaked / nature - Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04196-3In a study of four brain-dead human decedents, extracorporeal liver cross-circulation using genetically modified pig livers provides essential hepatic functions, supporting…
AI Summary: In a controversial translational study investigators ran blood between genetically modified pig livers and brain‑dead human decedents using an extracorporeal cross‑circulation system to assess organ viability and function. The work explores a potential bridge to expand transplantable organs, laying technical groundwork while prompting ethical and regulatory questions about next steps.